Protara Therapeutics raises $100M in public offering to fund TARA-002 clinical development

Protara Therapeutics, Inc.

Gross proceeds of ~$100M from offering of 13.69M shares and 2.33M pre-funded warrants at $6.25/share.
Proceeds to fund clinical development of TARA-002 for cancer and rare diseases; also working capital.
Underwriters granted 30-day option to purchase up to 2.4M additional shares; company and insiders have 60-day lock-up.
Offering closed December 11, 2024; TD Cowen, Cantor, LifeSci Capital, Oppenheimer & Co., Scotiabank acted as joint book-runners.
Pre-funded warrants exercisable at $0.001, with ownership limitation of 4.99% (adjustable to 19.99%).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.